NeoGenomics, Inc. (BMV:NEO)
Mexico · Delayed Price · Currency is MXN | Market Cap | 32.37B +115.5% |
| Revenue (ttm) | 13.45B +10.9% |
| Net Income | -1.79B |
| EPS | -13.91 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 57.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 40 |
| Open | 176.40 |
| Previous Close | 182.00 |
| Day's Range | 176.40 - 176.40 |
| 52-Week Range | 176.40 - 217.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About NeoGenomics
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
NeoGenomics announces settlement of voluntary disclosure to OIG-HHS
NeoGenomics (NEO) has finalized a civil settlement with the Department of Justice, or DOJ, on behalf of the Office of Inspector General of the U.S. Department of Health and Human…
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has fina...
NeoGenomics price target raised to $19 from $14 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics (NEO) to $19 from $14 and keeps a Buy rating on the shares. The firm adjusted targets in…
NeoGenomics price target raised to $16 from $11 at BofA
BofA raised the firm’s price target on NeoGenomics (NEO) to $16 from $11 and keeps a Neutral rating on the shares as part of the firm’s Q2 earnings preview for…
NeoGenomics launches FDA-approved PTEN IHC prostate Cancer ompanion diagnostic
NeoGenomics (NEO) announced the launch of PTEN IHC CDx, the first immunohistochemistry companion diagnostic test approved by the FDA for patients with prostate adenocarcinoma. The test identifies PTEN...
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagnostic test approved by the U.S. FDA for patients with prostate adenocarcinoma.
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results after the close of U.S. financial markets on Tuesday, July 28, 2026.
NeoGenomics appoints Starrett to its Board of Directors
NeoGenomics (NEO) announced the appointment of Carolyn Starrett to its Board of Directors. Starrett is currently the President of Starrett Advisory, an independent consulting and strategic advisory fi...
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors.
NeoGenomics announces pricing of $275M convertible senior notes offering
NeoGenomics (NEO) announced the pricing of its previously announced private offering of $275M aggregate principal amount of 0.75% convertible senior notes due 2032. The notes will be senior, unsecured...
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes.
NeoGenomics files to sell $275M of convertible senior notes due 2032
NeoGenomics (NEO) announced that it has commenced a private offering of $275M aggregate principal amount of convertible senior notes due 2032 to persons reasonably believed to be qualified institution...
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes.
NeoGenomics Transcript: Jefferies Global Healthcare Conference 2026
Q1 saw double-digit revenue growth, driven by clinical and NGS segments, with strategic focus on proprietary product development and margin expansion. Strong ASCO engagement, new product launches, and technology upgrades support sustained growth and improved efficiency.
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will showcase nine scientific abstracts at the 2026 ASCO Annual Meeting, May 29–June 2, 2026, in Chicago (booth #32130).
NeoGenomics Transcript: AGM 2026
The meeting covered board elections, executive compensation, equity plan amendments, and auditor ratification, with a quorum of 89.61% established. Voting results will be published in a Form 8-K, and no questions were raised during the Q&A.
Neo Performance Materials Announces C$100 Million Bought Deal Treasury Offering of Common Shares
The base shelf prospectus is accessible, and the prospectus supplement will be accessible within two business days through SEDAR+ The base shelf prospectus is accessible, and the prospectus supplement...
Neo Partners with Greenland Mines to Advance Sarfartoq Rare Earth Project
Strategic partnership positions Greenland Mines to lead exploration while Neo retains equity stake and offtake rights Strategic partnership positions Greenland Mines to lead exploration while Neo reta...
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in t...
NeoGenomics price target lowered to $11 from $13 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on NeoGenomics (NEO) to $11 from $13 and keeps a Neutral rating on the shares. 1 results were “modestly positive, though…
NeoGenomics price target raised to $14 from $13 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on NeoGenomics (NEO) to $14 from $13 and keeps a Buy rating on the shares. The firm said they reported…
Leerink upgrades NeoGenomics to Outperform, raises target to $25
As previously reported, Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a price target of $25, up from $12. The company delivers on its one-stop shop business model…
NeoGenomics upgraded to Buy from Hold at Benchmark
Benchmark upgraded NeoGenomics (NEO) to Buy from Hold with an $11 price target after the company reported better than expected revenue and in-line earnings and said it continues to plan…
NeoGenomics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded NeoGenomics (NEO) to Outperform from Market Perform with a $25 price target
NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c
Reports Q1 reveneue $187M, consensus $184.48M. “The first quarter of 2026 was a truly transformational one for NeoGenomics (NEO). We again delivered double-digit revenue growth while making meaningful...